Article Features Unique Nature of Export Agreement of Cannabis-Related Products From Southern California to Latin America
SAN DIEGO, CA–(Marketwired – December 29, 2016) – Medical Marijuana, Inc. (OTC PINK: MJNA), the first-ever publicly traded cannabis company in the United States, today announced that the Company, its subsidiary HempMeds® Mexico and its products were featured in an L.A. Weekly article focused on the first-ever import permit granted by Mexico for the cannabidiol (CBD) oil product Real Scientific Hemp Oil-X™ (RSHO-X™).
The Dec. 23, 2016, article titled “Mexico Begins Importing Medical Marijuana As Views on Therapeutic Cannabis Evolve” states, “The California-based company’s partnership with Mexico — an ally of particular interest thanks to cultural and historical ties that date back centuries — was solidified earlier this year when COFEPRIS, the Mexican health department, approved the country’s first permit allowing the import of hemp-based CBD oil across its border.” The article goes on to describe how the company worked with attorneys representing families — who then worked with COFEPRIS to develop a “THC-free” version, called RSHO-X™.
The article continues: “But in Mexico, cannabis-based treatment is viewed with suspicion and remains highly taboo. So when the Maldonado family discovered that another Mexican family had a child with the same kind of affliction, the two families combined their efforts and participated in a series of congressional hearings in Mexico City in January. On February 1, 2016, they were rewarded when COFEPRIS granted permits for the little girls to receive CBD treatments from abroad.”
“We are very humbled to have this opportunity,” the L.A. Weekly article quoted Medical Marijuana, Inc. CEO Dr. Stuart Titus as saying. “Today, we remain the only legal cannabis-based products allowed into the country and remain the only Botanical CBD company with a COFEPRIS import permit.”
The article also discussed Medical Marijuana, Inc. subsidiary HempMeds® Brasil receiving the first-ever import permit from the federal government of Brazil, stating: “Brazil has a similar arrangement with Medical Marijuana, Inc., whose hemp oil was first allowed in the country in 2014 on a case-by-case basis for the treatment of chronic pain, epilepsy and Parkinson’s disease.”
“We helped educate the government [in Brazil] and, going further, the government saw this product actually helped control these seizure disorders. Since there wasn’t a good pharmaceutical medication, the regulatory officials declared it would be “inhumane” to keep these products from the patients,” Titus was quoted as saying.
About Medical Marijuana, Inc.
Our mission is to be the premier cannabis and hemp industry innovators, leveraging our team of professionals to source, evaluate and purchase value-added companies and products, while allowing them to keep their integrity and entrepreneurial spirit. We strive to create awareness within our industry, develop environmentally-friendly, economically sustainable businesses, while increasing shareholder value. For details on Medical Marijuana, Inc.’s portfolio and investment companies, visit www.medicalmarijuanainc.com.
About HempMeds® Mexico
HempMeds® Mexico is a Mexico-based company that made history by being the first company to receive a COFEPRIS federal government import permit for the cannabis product RSHO-X™ for a medical indication. HempMeds® Mexico plans to work directly with the Mexican government to safely and legally provide access to CBD hemp oil products. For more information, please review the company’s website at: http://www.hempmeds.mx.
About HempMeds® Brasil
HempMeds® Brasil currently has three cannabis products approved for importation into Brazil as a prescription medication for Epilepsy, Parkinson’s and Chronic Pain. The company had the first-ever cannabis product allowed for import into Brazil and its products are currently subsidized by the Brazilian government, under their health care system, for all three medical indications listed above. HempMeds® Brasil is working on additional approvals for multiple indications.
This press release may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward-looking statements by definition involve risks, uncertainties and other factors, which may cause the actual results, performance or achievements of Medical Marijuana, Inc. to be materially different from the statements made herein.
FOOD AND DRUG ADMINISTRATION (FDA) DISCLOSURE
These statements have not been evaluated by the FDA and are not intended to diagnose, treat or cure any disease.
Medical Marijuana, Inc. does not sell or distribute any products that are in violation of the United States Controlled Substances Act (US.CSA). These companies do grow, sell, and distribute hemp-based products and are involved with the federally legal distribution of medical marijuana-based products within certain international markets. Cannabidiol is a natural constituent of hemp oil.
Public Relations Contact:
Chief Executive Officer
P. 888-829- 0070
Corporate Business Contact:
Medical Marijuana, Inc.
OTC Symbol: MJNA
Toll Free: 888-OTC- MJNA (888-682- 6562)